Our mission is to advance treatment discovery at a pace which helps our patients today. How do we accomplish this? Through progressive research and big data.
Dictionary.com defines “big data” as extremely large data sets that may be analyzed computationally to reveal patterns, trends, and associations . . .” Until now, big data has largely been applied to the commercial world, predicting human interactions and behaviors. Imagine if the same principles of big data in the commercial world applied to the medical world — driving research hypotheses, treatment protocols, and medical outcomes. This very idea powers the TPIRC clinical care and research model. TPIRC truly is where big data meets big medicine.
TPIRC is equipped with a state-of-the art research facility where discovery is driven by the study of millions upon millions of data points. With each case that we treat, we continue to grow our data sets at an exponential rate. This form of data collection and analysis opens the door for truly patient-driven research derived from real-world, clinical data and outcomes rather than laboratory hypotheses. This collection of shared information offers the greatest hope to truly advance treatment protocols for some of the most complex conditions.
This application of this model in both our clinic and our research center is what will enable us to fulfill our two-fold mission – to advance treatment discovery at a pace which helps our patients today, while building scalable models of success to accelerate the rate of research discovery for all diseases.
Dr. Nathan Marsteller comes to TPIRC from the University of Nebraska in Lincoln, where he completed both his Ph.D and post-doctorate at the renowned Food Allergy Research and Resource Program (FARRP). At UNL, Dr. Marsteller focused on developing animal models in both germ-free and conventional mice, molecular biology, immunology, and microbiology. His hands-on work was designed to advance allergenicity safety assessments of novel food proteins. Dr. Marsteller’s unique background and research expertise are ideally suited for TPIRC’s innovative research model. Under his leadership, TPIRC is studying the interactions of the immune system and genetic regulation as they relate to rare diseases – in particular, allergy and lung development. Dr. Marsteller aims to develop new diagnostic tools to define and understand novel immune biomarkers. As understanding of these biomarkers grows, TPIRC is uniquely positioned to identify the underpinning mechanisms of the rare diseases we treat – further advancing our mission to provide cutting-edge care and drive treatment discovery at a pace which helps our patients today.